Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Impact Of Bortezomib On 1q21+ In Multiple Myeloma: A Meta-analysis Of Treatment Outcomes And Prognostic Implications

Impact of bortezomib on 1q21+ in multiple myeloma: A meta-analysis of treatment outcomes and prognostic implications

Xiaona Zheng1, Siyu Lin1, Kejie Lu1

  • 1Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 610041 P.R. China.

Oncology Letters
|November 4, 2024

Related Experiment Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.2K

View abstract on PubMed

Summary
This summary is machine-generated.

The gain of chromosome 1q21 (1q21+) is a high-risk factor in multiple myeloma (MM). Bortezomib treatment improved complete response rates for 1q21+ MM patients, but did not overcome the associated poor prognosis.

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • The 1q21 chromosomal region gain (1q21+) is a significant adverse prognostic factor in multiple myeloma (MM).
  • Bortezomib-based regimens have improved MM patient outcomes, but its impact on 1q21+ patients remains debated.

Purpose of the Study:

  • To evaluate the efficacy of bortezomib in mitigating the poor prognosis associated with 1q21+ in multiple myeloma.
  • To analyze the impact of 1q21+ on complete response (CR), overall survival (OS), and progression-free survival (PFS) in MM patients treated with bortezomib.

Main Methods:

  • A meta-analysis of 6 studies involving 1,575 multiple myeloma patients.
  • Evaluation of CR, OS, and PFS rates in patients with and without 1q21+ undergoing bortezomib-based treatment.
Keywords:
1q21+bortezomibhigh-risk factormultiple myeloma

Related Experiment Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.2K

Main Results:

  • Patients with 1q21+ showed a higher likelihood of achieving CR with bortezomib treatment (OR, 0.64; 95% CI, 0.49-0.83).
  • However, 1q21+ remained a significant high-risk factor, negatively impacting PFS (HR, 1.72; 95% CI, 1.53-1.93) and OS (HR, 1.95; 95% CI, 1.58-2.42).

Conclusions:

  • Bortezomib treatment enhances CR rates in multiple myeloma patients with 1q21+.
  • Despite improved CR, 1q21+ continues to signify a high-risk status in MM patients receiving bortezomib-based therapy.